Akgun Ince MD

Rheumatoid Arthritis & Related

Clinical Professor of Medicine at Saint Louis University School of Medicine Chief of Rheumatology at Mercy Hospital St.Louis

Join to view full profile

522 N New Ballas RdSuite 240St. Louis, MO 63141
Phone+1 314-567-5100
Fax+1 314-567-3387

Dr. Ince is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Ince's full profile Already have an account?

Summary

Dr. Akgun Ince is a rheumatologist based in Saint Louis, MO, specializing in rheumatoid arthritis and related conditions. He completed his medical education at Istanbul University, followed by a fellowship in rheumatology and a residency in internal medicine at SSM Health/Saint Louis University School of Medicine. Dr. Ince served as a professor at Saint Louis University from 2008 to 2011. He co-authored a study on the health-related quality of life impacts of intravenous Golimumab in ankylosing spondylitis patients, published in 2020. His clinical trial work includes studies on Ixekizumab for various forms of axial spondyloarthritis and rheumatoid arthritis. He has received several honors, including CMS Meaningful Use Stage 1 Certification and being named a Fellow of the American College of Rheumatology.

Education & Training

SSM Health/Saint Louis University School of MedicineResidency, Internal Medicine, 1996 - 1998
SSM Health/Saint Louis University School of MedicineFellowship, Rheumatology, 1994 - 1996
Istanbul University FomClass of 1989

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

MO State Medical License 1998 - 2027
IL State Medical License 1996 - 2005
IA State Medical License 1995 - 1997
American Board of Internal Medicine Rheumatology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification eClinicalWorks, eClinicalWorks, LLC, 2013-2017
CMS Meaningful Use Stage 2 Certification eClinicalWorks, eClinicalWorks, LLC, 2013-2017
CMS Meaningful Use Stage 1 Certification eClinicalWorks EHR, eClinicalWorks LLC, 2012-2013

Clinical Trials

An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis Start of enrollment: 2013 Jun 27
COMPLETED
PHASE3
A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis Start of enrollment: 2016 May 02
COMPLETED
PHASE3
A Study of Ixekizumab (LY2439821) in TNF Inhibitor Experienced Participants With Radiographic Axial Spondyloarthritis Start of enrollment: 2016 Apr 12
COMPLETED
PHASE3

Publications & Presentations

PubMed

Assessing Rheumatoid Arthritis Disease Activity Measures in Ethnic Minority Patients in the United States: Real-World Data From the Ethnic Minority Rheumatoid Arthriti...
Mercedes Quiñones, Sharon Dowell, Rodolfo Perez Alamino, Christopher J Swearingen, Edward Treadwell
Journal of Clinical Rheumatology. 2025-12-01
5 citations
Effects of Intravenous Golimumab on Health-Related Quality of Life in Patients with Ankylosing Spondylitis: 28-Week Results of the GO-ALIVE Trial.
John D. Reveille, Atul Deodhar, Akgun Ince, Eric K. H. Chan, S. Peterson
Value in Health. 2020-10-01